- Home
- CABA vs AEYE Comparison
CABA vs AEYE Comparison
Compare CABA & AEYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CABA
- AEYE
- Stock Information
- Founded
- CABA 2017
- AEYE 2005
- Country
- CABA United States
- AEYE United States
- Employees
- CABA N/A
- AEYE N/A
- Industry
- CABA Biotechnology: Biological Products (No Diagnostic Substances)
- AEYE Computer Software: Prepackaged Software
- Sector
- CABA Health Care
- AEYE Technology
- Exchange
- CABA Nasdaq
- AEYE Nasdaq
- Market Cap
- CABA 118.8M
- AEYE 138.0M
- IPO Year
- CABA 2019
- AEYE N/A
- Fundamental
- Price
- CABA $1.79
- AEYE $11.81
- Analyst Decision
- CABA Strong Buy
- AEYE Strong Buy
- Analyst Count
- CABA 8
- AEYE 5
- Target Price
- CABA $18.88
- AEYE $26.40
- AVG Volume (30 Days)
- CABA 2.5M
- AEYE 68.7K
- Earning Date
- CABA 08-07-2025
- AEYE 07-24-2025
- Dividend Yield
- CABA N/A
- AEYE N/A
- EPS Growth
- CABA N/A
- AEYE N/A
- EPS
- CABA N/A
- AEYE N/A
- Revenue
- CABA N/A
- AEYE $36,851,000.00
- Revenue This Year
- CABA N/A
- AEYE $20.16
- Revenue Next Year
- CABA N/A
- AEYE $18.74
- P/E Ratio
- CABA N/A
- AEYE N/A
- Revenue Growth
- CABA N/A
- AEYE 16.52
- 52 Week Low
- CABA $0.99
- AEYE $8.91
- 52 Week High
- CABA $9.25
- AEYE $34.85
- Technical
- Relative Strength Index (RSI)
- CABA 47.69
- AEYE 46.36
- Support Level
- CABA $1.56
- AEYE $11.27
- Resistance Level
- CABA $2.02
- AEYE $12.17
- Average True Range (ATR)
- CABA 0.24
- AEYE 0.57
- MACD
- CABA -0.06
- AEYE -0.08
- Stochastic Oscillator
- CABA 22.33
- AEYE 32.14
About CABA Cabaletta Bio Inc.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) has the potential to be applied across a broad range of autoimmune diseases.
About AEYE AudioEye Inc.
AudioEye Inc is a software solution provider delivering immediate ADA and WCAG accessibility compliance at scale. Through patented technology, subject matter expertise and proprietary processes, it is eradicating all barriers to digital accessibility, helping creators get accessible and supporting them with ongoing advisory and automated upkeep. Trusted by the ADP, Tommy Hilfiger, A360 Media, Samsung, Landry's and others. It helps everyone identify and resolve issues of accessibility and enhance user experiences, automating digital accessibility for the widest audiences.